Cure Today

Aphexda Plus Filgrastim Boosts Stem Cell Mobilization in Patients With Myeloma

The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...
ascopubs.org

Randomized Trial of Filgrastim, Sargramostim, or Sequential Sargramostim and Filgrastim After Myelosuppressive Chemotherapy for the Harvesting of Peripheral-Blood Stem Cells

PURPOSE: The purpose of this study was to compare the effects of filgrastim, sargramostim, or sequential sargramostim and filgrastim on CD34 + cell yields and morbidity after myelosuppressive ...
ascopubs.org

High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34 + Immunoselection

Interobserver Variability in the Detection of Cervical-Thoracic Hodgkin's Disease by Computed Tomography PURPOSE: The efficacy of a high- versus a standard-dose filgrastim (recombinant human ...
WTNH

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma ...

GENESIS (NCT 03246529) is a 2-part, Phase-3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of APHEXDA (motixafortide) plus filgrastim (G-CSF), ...
Seeking Alpha

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple ...

TEL AVIV, Israel, May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that ...